65,437 trials
Siblings · Childhood Cancer · Pediatric Cancer
Primary: Child Posttraumatic Stress Disorder Symptom Scale for DSM-5 — 15.3 units on a scale
Advanced Rare Tumours
Primary: Objective Response Rate Measured by RECIST Version 1.1 — 1; 19; 32; 76 Participants
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Percent of Participants With 6-month Progression-free Survival (PFS6) — 33 percent of participants
Parkinson Disease
Primary: Fluency Composite From NIH Examiner (Kramer et al., 2014). — 0.334; -0.0287 z-score — p=.077
Covid19
Primary: Number of Subjects With Serious Adverse Events — 0; 1 Participants
Classical Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants
HIV/AIDS
Primary: Number of Virally Suppressed Participants — 97; 94; 79; 89 Participants
Ewing Sarcoma · PEComa · Epithelioid Sarcoma
Primary: Maximum Tolerated Dose of ABI-009 — 100 mg/m^2
Biliary Atresia
Primary: Mean Change in Total Serum Bilirubin Levels — -3.5; -3.11 mg/dl — p=0.7419
Multiple Sclerosis, Relapsing-Remitting
Primary: Change in Peripheral B-cell Tolerance Checkpoints in People With MS Before and After Ocrelizumab Therapy.
Jansky-Bielschowsky Disease · Batten Disease · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
Primary: Motor Language (ML) Scale: Rate of Decline in the 0 to 6-point ML Score. — 0.15; 1.30 change in score/48 wk — p=< 0.0001
Type 1 Diabetes
Primary: Primary Safety Endpoint - Change in HbA1c — -0.4; -0.7 percentage of HbA1c — p=<0.001
Diabetes Mellitus, Type 1
Primary: FMD/Shear — 0.182; 0.206; 0.155; 0.219 %/s^-1
Acromegaly
Primary: Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level — -0.034 ng/mL x ULN — p=0.6285
Cyclic Vomiting Syndrome
Primary: State-Trait-Anxiety Inventory (STAI) (18) and Profile of Mood States (POMS) — 34.59; 35.05; 26.27; 41.67 score on a scale